Biologics
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
Clinigen's CEO and senior executives outline how the services company navigated Japan’s rigorous regulatory framework to secure approval for Prolacta’s human milk–based fortifier as a prescription biological product.
Cipla will form a 60:40 joint venture with Kemwell Biopharma to develop, manufacture and commercialize biologics for global markets. The India-based venture will leverage Kemwell’s Bengaluru biologics facility and support development, licensing, and export of biologic products.
The Phase I/II study’s trial page was updated to say it was no longer recruiting patients after recruiting only 23 of the originally planned 260.
Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.
Aviv Regev is betting AI-driven drug discovery can transform Genentech's pipeline, with early wins validating her computational biology approach to pharmaceutical R&D.
In this episode of the In Vivo podcast, Lupus Therapeutics' Stacie Bell discusses transforming lupus drug development through patient-centered clinical trials, promising new oral therapies and revolutionary cell therapy approaches.
Halozyme’s move to acquire the developer of subcutaneous drug-delivery technology for biologics expands its options for partnering and developing products available for at-home and health care provider office delivery.
Multiple Korean ministries, biopharma companies, and other officials convened at a bio innovation roundtable to discuss strategies to emerge as a global biopharma powerhouse.
“We’ve invested billions of dollars and have achieved over $12bn in revenues since we launched our first biosimilars,” Amgen’s biosimilars head, Marc Doble, tells Generics Bulletin as part of an exclusive interview, which explores how the firm’s biosimilars benefit from its roots in biologics.
Merck and Lilly are among the leading pharma players using space-based research to power drug development. From reusable satellites to process drugs in low earth orbit to biomanufacturing labs experts discuss R&D opportunities in the starry canvas above.
Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.